368: PARP1 and Amyloid: Protecting Neurons in a Familial AD Model

Jhaldiyal A et al., PNAS - This episode summarizes a PNAS study showing that PARP1 activation links Aβ1-42 toxicity to DNA damage, amyloid accumulation, neuroinflammation, and cognitive deficits, and that genetic or pharmacologic PARP1 suppression reduces pathology in cells and 5XFAD mice. Key terms: PARP1, poly(ADP-ribose), Alzheimer's disease, amyloid beta, neurodegeneration.

Study Highlights:
CSF poly(ADP-ribose) (PAR) is elevated in patients with MCI and AD and negatively correlates with the Aβ42/40 ratio. Oligomeric Aβ1-42 activates PARP1 in primary cortical neurons, causing DNA damage and cell death that are prevented by PARP1 inhibitors or PARP1 genetic deletion. In 5XFAD mice, PARP1 knockout halves plaque burden, preserves synapses and neurons, reduces glial activation and inflammatory gene expression, and rescues spatial learning and memory. Mechanistically, PARP1 deficiency lowers BACE1, alters γ-secretase subunits (PSEN1 up, nicastrin down), and increases the Aβ-degrading enzyme NEP2.

Conclusion:
PARP1 is a critical mediator of Aβ-driven toxicity, amyloid accumulation, neuroinflammation, and cognitive decline in a familial AD model, and its inhibition may be a promising disease-modifying strategy.

Music:
Enjoy the music based on this article at the end of the episode.

Article title:
PARP1 deficiency mitigates amyloid pathology, neurodegeneration, and cognitive decline in a familial Alzheimer’s disease model

First author:
Jhaldiyal A

Journal:
PNAS

DOI:
10.1073/pnas.2525028123

Reference:
Jhaldiyal A., Kumari M., Guttman L. C., et al. PARP1 deficiency mitigates amyloid pathology, neurodegeneration, and cognitive decline in a familial Alzheimer’s disease model. PNAS (2026). DOI: 10.1073/pnas.2525028123

License:
This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/

Support:
Base by Base – Stripe donations: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00

Official website https://basebybase.com

On PaperCast Base by Base you'll discover the latest in genomics, functional genomics, structural genomics, and proteomics.

Episode link: https://basebybase.com/episodes/parp1-amyloid-neurodegeneration-5xfad

QC:
This episode was checked against the original article PDF and publication metadata for the episode release published on 2026-05-16.

QC Scope:
- article metadata and core scientific claims from the narration
- excludes analogies, intro/outro, and music
- transcript coverage: Audited the transcript sections describing CSF PAR elevation, Aβ42-induced PARP1 activation in neurons, in vitro neuroprotection by PARP inhibitors, in vivo 5XFAD/PARP1−/− outcomes (plaque burden, neuronal survival, gliosis, cognitive tests), APP metabolism changes, NEP2 involvement, inflammation, and translational cav
- transcript topics: CSF PAR elevation in MCI and AD and relation to Aβ42/40; Oligomeric Aβ42 activates PARP1 and induces DNA damage; Pharmacologic/genetic PARP1 inhibition confers neuroprotection in vitro; 5XFAD/PARP1−/− mice: reduced amyloid plaque burden and neuronal loss; APP processing changes: BACE1 reduction, PSEN1/nicastrin alterations, NEP2 up; Neuroinflammation and gliosis attenuation with PARP1 loss

QC Summary:
- factual score: 10/10
- metadata score: 10/10
- supported core claims: 6
- claims flagged for review: 0
- metadata checks passed: 4
- metadata issues found: 0

Metadata Audited:
- article_doi
- article_title
- article_journal
- license

Factual Items Audited:
- CSF PAR levels are elevated in MCI and AD and inversely correlate with the Aβ42/40 ratio
- Oligomeric Aβ1-42 activates PARP1 and induces DNA damage; PARP1 inhibition or deletion confers neuroprotection in vitro
- PARP1 deficiency in 5XFAD mice reduces plaque burden (~50%) and preserves neurons and synapses while reducing gliosis and neuroinflammation
- PARP1 deficiency lowers APP processing toward reduced Aβ production (BACE1 decreased; PSEN1 up; nicastrin down) and increases NEP2-mediated Aβ degradation
- PARP inhibitors (e.g., veliparib, rucaparib, talazoparib) block Aβ-induced PAR accumulation and protect neurons in culture
- Translational considerations include blood-brain barrier crossing and long-term safety concerns for chronic PARP inhibition

QC result: Pass.